Bioequivalence study of an open-label, randomized, two-way crossover design with two-period, two-treatment, two-sequence of test product lynestrenol 0.5 mg tablets and reference product (ExlutonÂ®) in healthy Thai female volunteers under fasting cond

Start Date01 Mar 2021

Sponsor / Collaborator

Chiang Mai University

[+1]

NCT02715232 / Unknown statusPhase 4IIT

Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET

The aim of this study is to prove the modulatory influence of sex hormones on serotonergic neurotransmission by determining the enzymatic processes involved in serotonin synthesis and degradation using positron emission tomography (PET) in humans in vivo with the radiotracers [11C]AMT and [11C]harmine.

Start Date06 Feb 2017

Sponsor / Collaborator

Medical University of Vienna

NCT01065220 / CompletedPhase 4IIT

The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography

The aim of this study is to prove the influence of the sex steroid hormones estrogen, progesterone and testosterone on the serotonin transporter (5-HTT) binding using positron emission tomography (PET) and the selective radioligand [11C]DASB. Specifically, the 5-HTT binding will be quantified before and after hormone therapy underwent by 10 male-to-female (MtF) and 10 female-to-male (FtM) transsexuals urging for hormone treatment. The high-level, long-term administration of opsite sex steroid hormones in transsexuals provide the unique opportunity to investigate the influence of sex steroid hormones on the serotonergic system. Since the serotonin transporter serves as a primary target molecule for antidepressant treatment, the results of the study will be of benefit for the assessment of the clinical relevance of estrogen and testosterone as modulatory and neuroactive agents.

Start Date01 Feb 2010

Sponsor / Collaborator

Medical University of Vienna

100 Clinical Results associated with Lynestrenol

100 Translational Medicine associated with Lynestrenol

100 Patents (Medical) associated with Lynestrenol

396

Literatures (Medical) associated with Lynestrenol

01 Apr 2024·Journal of Pediatric and Adolescent Gynecology

Progestins as a Contributing Factor to Hepatocellular Adenoma: A Case Series and Literature Review

Review

Author: Grover, Sonia R ; Moussaoui, Dehlia

STUDY OBJECTIVETo explore the role of progestins as potential contributing factors for the development of hepatocellular adenoma (HA) METHODS: We describe 3 cases of adolescents and young adults who developed HA while on norethindrone (NET), as well as their management. In addition, we provide a comprehensive literature review on the association between progestins and HA.RESULTSSince 1983, 16 cases of HA in patients on progestins have been reported. Ten patients were on NET and 5 on a prodrug of NET (4 on norethindrone acetate [NETA] and 1 on lynestrenol). One individual had a norgestrel implant. Eight subsequently ceased all hormones: 4 experienced a size reduction, and 3 had complete resolution of their HA. Among our patients, 1 ceased NET and instead had a levonorgestrel intrauterine device inserted, and another swapped from NET to oral medroxyprogesterone acetate. Both experienced complete resolution of their HA. The third ceased NET and underwent a hysterectomy, with size reduction of her HA.CONCLUSIONThese cases and the literature review suggest an association between progestin exposure, in particular NET and its prodrugs, and the development of HA. The pathophysiology is unknown but may include peripheral conversion of NET and NETA to ethinyl estradiol or a specific action of 19-nortestosterone derivatives on hepatocytes, especially those with higher systemic doses compared with the levonorgestrel intrauterine device. There are no case reports relating to other forms of progestins, such as 17-hydroxyprogesterone, which may be important when considering alternative therapeutic options in females requiring effective menstrual management who have comorbidities.

01 Oct 2023·Blood Coagulation & Fibrinolysis

Protein C and protein S deficiencies are associated with increased risk of deep vein thrombosis in pregnant women using oral contraceptives

Article

Author: Osman, Hussam Ali ; Algarni, Abdulrahman ; Babker, Asaad M.A. ; Ahmed, Osama A.B. ; Elfaki, Elyasa M. ; Habiballah, Eldaw M. ; Hamza, Alneil ; Kumar, Praveen ; Yousif, Tagwa Yousif Elsayed ; Alfeel, Ayman H. ; Abdalhabib, Ezeldine K. ; Elzein, Husham O. ; Saboor, Muhammad

BackgroundOral contraceptives are commonly taken by women and are known to increase the risk of venous thromboembolism (VTE).ObjectiveThe aim of this study was to investigate the association between oral contraceptive use and natural anticoagulants, that is, protein C (PC), protein S (PS), and antithrombin in pregnant women with deep vein thrombosis (DVT).Materials and methodsThis case–control study was conducted on 330 pregnant women, that is, cases 165 (who used oral contraceptives) and controls 165 (who did not use oral contraceptives). The levels of PC, PS, and antithrombin were measured and compared between the two groups. The use of different types of oral contraceptives and their association with DVT and PC and PS were also analyzed.ResultsThe study found that women with DVT had significantly lower levels of PC and PS compared with controls (P < 0.001). However, no significant difference was found in the levels of AT. Among the different types of oral contraceptives, first-generation progestin pills including Ethynodiol Diacetate, Norethindrone Acetate, Norethynodrel, and second-generation oral contraceptives (Lynestrenol, Levonorgestrel and Norgestrel) were not found to be associated with lower levels of PC and AT while Desogestrel, Norgestimate, and Gestodene (third-generation) were associated with lower levels of PS.ConclusionThis study suggests that the use of contraceptives, particularly those containing Desogestrel, Norgestimate, and Gestodene, may be associated with a higher risk of thrombosis because of the associated lower levels of PS. Monitoring anticoagulant levels is crucial in preventing DVT in this population.

01 May 2022·Obstetrics & Gynecology

Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy

Article

Author: Chacon, Silvia Segovia ; Kopp-Kallner, Helena ; Linder, Marie ; Cesta, Carolyn E. ; Kieler, Helle ; Graner, Sofie

OBJECTIVE:To estimate the incidence rates for ectopic pregnancy by contraceptive method in a cohort of women using hormonal contraception in Sweden between 2005 and 2016.METHOD:Women aged 15–49 years with a filled prescription for a hormonal contraceptive in the Swedish Prescribed Drug Register between 2005 and 2016 were included. For each woman, all exposed woman-years were allocated to treatment episodes depending on the method of contraception. Treatment time started on the day the prescription was filled and ended on the first day of the end of supply, new eligible dispensing, pregnancy-related diagnosis and its associated estimated last menstrual period, or removal procedure. Ectopic pregnancy was defined as having at least two records of International Classification of Diseases, Tenth Revision code O00-, including O00.0, O00.1, O00.2, O00.8, O00.9, within 30 days or one episode of O00- and one surgical procedure for ectopic pregnancy (NOMESCO Classification of Surgical Procedures code LBA, LBC, LBD, LBE, LBW). Incidence rates per 1,000 woman-years and 95% CIs were calculated for each method of contraception.RESULTS:The study included 1,663,242 women and 1,915 events of ectopic pregnancy. The incidence rate (95% CI) for ectopic pregnancy per method of hormonal contraception was estimated: 13.5-mg levonorgestrel (LNG) hormonal intrauterine device (IUD), 2.76 (2.26–3.35) per 1,000 woman-years; 52-mg LNG hormonal IUD, 0.30 (0.28–0.33) per 1,000 woman-years; combined oral contraception, 0.20 (0.19–0.22) per 1,000 woman-years; progestogen implants, 0.31 (0.26–0.37) per 1,000 woman-years; oral medium-dose progestogen (desogestrel 75 mg), 0.24 per 1,000 woman-years, (0.21–0.27); and oral low-dose progestogen (norethisterone 0.35 mg and lynestrenol 0.5 mg), 0.81 (0.70–0.93) per 1,000 woman-years.CONCLUSION:Hormonal contraception lowers the risk of ectopic pregnancy markedly. The incidence rate of ectopic pregnancy among women using a low-dose hormonal IUD (13.5 mg LNG) was substantially higher than that in women using other types of hormonal contraception. This study provides real-world evidence to inform best clinical practice for women-centered contraceptive counseling.

100 Deals associated with Lynestrenol

External Link

KEGG	Wiki	ATC	Drug Bank
D01580	Lynestrenol	G03AC02 G03DC03	DB12474

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Contraception	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis